Ligand Pharmaceuticals (LGND) Change in Acquisitions & Divestments (2010 - 2026)

Ligand Pharmaceuticals has disclosed Change in Acquisitions & Divestments across 16 years of filings, most recently posting $119.4 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $119.4 million, up 210.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $240.5 million (up 2163.5% YoY), and the FY2025 annual result was $159.6 million, up 381.68% from the prior year.
• Change in Acquisitions & Divestments came in at $119.4 million for Q1 2026 at Ligand Pharmaceuticals, up from $23.1 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $119.4 million in Q1 2026 to a low of -$71.2 million in Q3 2024.
• The 5-year median for Change in Acquisitions & Divestments is $31.4 million (2022), against an average of $27.3 million.
• Peak annual rise in Change in Acquisitions & Divestments reached 619.66% in 2024, while the deepest fall reached 194.06% in 2024.
• Ligand Pharmaceuticals' Change in Acquisitions & Divestments stood at $24.8 million in 2022, then tumbled by 305.06% to -$50.9 million in 2023, then surged by 110.57% to $5.4 million in 2024, then soared by 328.98% to $23.1 million in 2025, then surged by 417.14% to $119.4 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $119.4 million (Q1 2026), $23.1 million (Q4 2025), and $53.3 million (Q3 2025), per Business Quant data.